Skip to main content

Ovid Therapeutics Inc.

OVID
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001636651

No open-market purchases or sales by Ovid Therapeutics Inc. insiders were filed in the last 90 days; 130 institutions reported holding it in 13F filings for Q2 2026, worth $395.5M in total; no superinvestor holds it.

Q2 2024 vs. Q1 2024

How the institutions holding Ovid Therapeutics Inc. changed between Q1 2024 and Q2 2024.

All holders in Q2 2024All holders in Q1 2024

13F holders of OVID: Q1 2024 compared with Q2 2024
MeasureQ1 2024Q2 2024Change
Holders8174−7
Shares50.1M46.0M−4.09M (−8.2%)
Value$152.8M$35.4M−$117.4M (−76.8%)

New holders (14)

Institutions that held Ovid Therapeutics Inc. at the end of Q2 2024 but not at the end of Q1 2024.

Institutions new to OVID in Q2 2024
InstitutionSharesValue% of portfolio
Kennedy Capital Management, Inc.1,488,571$1.15M0.02%
Driehaus Capital Management LLC1,400,191$1.08M0.01%
Gsa Capital Partners LLP119,507$92.0K0.01%
Alliancebernstein L.P.47,880$36.8K0.00%
Corebridge Financial, Inc.31,683$24.4K0.00%
Mirae Asset Global ETFs Holdings Ltd.30,913$23.8K0.00%
XTX Topco Ltd26,154$20.1K0.00%
Knott David M Jr20,000$15.0K0.01%
BBR Partners, LLC12,495$9.61K0.00%
Baader Bank INC13,282$8.32K0.00%
Federated Hermes, Inc.2,250$1.73K0.00%
Mirae Asset Global Investments Co., Ltd.2,118$1.54K0.00%
Russell Investments Group, Ltd.1,598$1.23K0.00%
Nisa Investment Advisors, LLC143$1100.00%

Sold out (21)

Institutions that held Ovid Therapeutics Inc. at the end of Q1 2024 and filed for Q2 2024 without it.